Abiopharma

🔍 Gilboa David Abraham (Director)

Company: Warby Parker Inc. (WRBY)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 75,000 shares of Class A Common Stock (Direct)
  Date: 2026-01-07 | Code: C | equity_swap_involved: 0 | shares_owned_after: 112,247.00 | transaction_form_type: 4
• Sold 75,000 shares of Class A Common Stock at $27.09 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,247.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 19,906 shares of Class A Common Stock (Direct)
  Date: 2026-01-09 | Code: C | equity_swap_involved: 0 | shares_owned_after: 57,153.00 | transaction_form_type: 4
• Sold 19,906 shares of Class A Common Stock at $29.09 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,247.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 75,000 shares of Class B Common Stock (Derivative)
  Date: 2026-01-07 | Code: C | equity_swap_involved: 0 | shares_owned_after: 4,709,923.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 19,906 shares of Class B Common Stock (Derivative)
  Date: 2026-01-09 | Code: C | equity_swap_involved: 0 | shares_owned_after: 4,690,017.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Holds 1,656,770 shares of Class B Common Stock (Derivative)
  Date: 2026-01-07 | Code: H | shares_owned_after: 1,656,770.00 | Footnotes: F4, F4, F4

Footnotes:

• F1: These share sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2025.
• F2: The price reported in Column 4 is an average execution price rounded to the nearest hundredth. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.23 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
• F3: The price reported in Column 4 is an average execution price rounded to the nearest hundredth. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.20 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
• F4: The Class B Common Stock is convertible at any time at the option of the holder into the Issuer's Class A Common Stock on a one-to-one basis. The Class B Common Stock will automatically convert into shares of the Issuer's Class A Common Stock on a one-to-one basis upon the earlier of (i) transfer of Class B Common Stock to a person or entity that is not in the transferor's permitted ownership group, (ii) October 1, 2031, (iii) with respect to any Class B Common Stock held by any person or entity in Neil Blumenthal's permitted ownership group, (A) such time as Neil Blumenthal is removed or resigns from the board of directors, or otherwise ceases to serve as a director, (B) such time as Neil Blumenthal ceases to be either an employee, officer or consultant of the Company or any of its subsidiaries, or (C) the date that is 12 months after the death or disability of Neil Blumenthal,
• F5: and (iv) with respect to any Class B common stock held by any person or entity in Dave Gilboa's permitted ownership group, (A) such time as Dave Gilboa is removed or resigns from the board of directors, or otherwise ceases to serve as a director, (B) such time as Dave Gilboa ceases to be either an employee, officer or consultant of the Company or any of its subsidiaries, or (C) the date that is 12 months after the death or disability of Dave Gilboa.